The power of creatine plus resistance training for healthy aging: enhancing physical vitality and cognitive function

The researchers examined the combined effect of creatine monohydrate supplementation plus resistance training versus resistance training plus placebo, across multiple studies. The intervention was creatine at doses ranging from 3–20 g/day (most commonly 5 g/day), often with a loading phase of 20 g/day for 5–7 days. Resistance training programmes varied but typically involved 2–4 sessions per week, targeting major muscle groups, for 8–52 weeks. Outcome measures included:

• Body composition: Lean body mass, fat mass, bone mineral density
• Strength: Upper body (bench press 1-rep max), lower body (leg press, leg extension 1-rep max), handgrip strength
• Functional performance: Chair stand test, timed up-and-go, gait speed, 6-minute walk test
• Cognitive function: Global cognition (Mini-Mental State Examination, Montreal Cognitive Assessment), working memory, executive function, processing speed
• Safety: Kidney function (creatinine, blood urea nitrogen), liver enzymes, adverse events

The meta-analysis pooled data from 15 randomised controlled trials involving a total of 650 participants (range per study: 16–100). All participants were adults aged 50 years and older (mean ages across studies ranged from 55 to 78 years). Some studies included only healthy community-dwelling older adults; others included adults with sarcopenia, frailty, or mild cognitive impairment. Both men and women were included, though some studies were male-only or female-only. Participants were generally sedentary or recreationally active at baseline — none were elite athletes. Exclusion criteria across studies typically included: chronic kidney disease, liver disease, diabetes requiring insulin, uncontrolled hypertension, recent myocardial infarction, and use of medications affecting muscle metabolism (e.g., corticosteroids).

Each included study used standardised instruments:

• Lean body mass: Dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA)
• Strength: 1-repetition maximum (1RM) testing on weight machines (bench press, leg press, leg extension) or handgrip dynamometry
• Functional performance: Chair stand test (number of stands in 30 seconds), timed up-and-go (seconds), gait speed (m/s over 4–6 metres), 6-minute walk distance (metres)
• Cognitive function: Mini-Mental State Examination (MMSE, 0–30, higher = better), Montreal Cognitive Assessment (MoCA, 0–30, higher = better), digit span forward/backward (working memory), Stroop test (executive function), trail making test (processing speed)
• Safety: Serum creatinine, blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase, self-reported adverse events

Study design: This is a systematic review and meta-analysis of randomised controlled trials (RCTs). The authors searched PubMed, Scopus, Web of Science, and Cochrane Library up to October 2023. They included only RCTs that compared creatine plus resistance training versus placebo plus resistance training in adults aged 50+. Fifteen trials met inclusion criteria.

Randomisation and blinding: All included studies were RCTs. Most were double-blind (participants and researchers unaware of group assignment), though some were single-blind. Creatine and placebo (typically maltodextrin or rice flour) were provided in identical-looking packets. Allocation concealment was reported in most but not all studies.

Duration: Intervention periods ranged from 8 to 52 weeks. The median duration was 12 weeks. Some studies included a loading phase (20 g/day for 5–7 days) followed by a maintenance phase (3–5 g/day). Others used a fixed dose throughout.

Statistical approach: The authors used random-effects meta-analysis (DerSimonian-Laird method) to pool effect sizes, reported as standardised mean differences (SMD) or mean differences (MD) with 95% confidence intervals. Heterogeneity was assessed using I² statistics. Publication bias was evaluated with funnel plots and Egger's test. Subgroup analyses were performed by sex, age group (50–65 vs. 65+), baseline cognitive status, creatine dose, and training duration.

What this design can and cannot prove: A meta-analysis of RCTs is the highest level of evidence for causal inference — it can tell us that creatine plus resistance training causes improvements in muscle mass and strength compared to resistance training alone. However, because the individual studies varied in protocols, populations, and outcome measures, the pooled estimates have limitations. The meta-analysis cannot tell us the optimal dose, duration, or training programme for every individual. It also cannot separate the effects of creatine from the effects of resistance training — it only tests the combination versus training alone. Importantly, the cognitive findings come from a small number of studies (only 4–6 trials contributed to cognitive outcomes), so those results are less robust.

Major methodological weaknesses: The authors note high heterogeneity for some outcomes (e.g., lean body mass I² = 72%), meaning the true effect varies considerably across studies. Several studies had small sample sizes (n < 30 per group). Some trials did not control for dietary creatine intake from meat/fish. Compliance with supplementation was not always verified. Industry funding was present in some studies (creatine manufacturers), though the authors declare no conflicts of interest.

Primary outcomes — body composition and strength:

• Lean body mass: Creatine + resistance training increased lean body mass by a mean difference of 1.37 kg (95% CI: 0.72 to 2.02 kg, p < 0.001) compared to resistance training + placebo. This represents a ~2–3% gain over 8–12 weeks.
• Upper body strength (bench press 1RM): Mean increase of 5.2 kg (95% CI: 3.1 to 7.3 kg, p < 0.001) favouring creatine. Relative improvement: ~8–12% greater than placebo.
• Lower body strength (leg press 1RM): Mean increase of 12.4 kg (95% CI: 7.8 to 17.0 kg, p < 0.001). Relative improvement: ~6–10% greater than placebo.
• Handgrip strength: Small but significant increase of 1.8 kg (95% CI: 0.6 to 3.0 kg, p = 0.004).

Secondary outcomes — functional performance:

• Chair stand test (30 seconds): Mean improvement of 1.6 additional stands (95% CI: 0.8 to 2.4, p < 0.001).
• Timed up-and-go: Mean reduction of 0.7 seconds (95% CI: −1.1 to −0.3 seconds, p = 0.001).
• Gait speed: Mean increase of 0.05 m/s (95% CI: 0.01 to 0.09 m/s, p = 0.02).
• 6-minute walk distance: Mean increase of 18.4 metres (95% CI: 5.2 to 31.6 metres, p = 0.006).

Tertiary outcomes — cognitive function:

• Global cognition (MMSE/MoCA): Small but significant improvement (SMD = 0.28, 95% CI: 0.06 to 0.50, p = 0.01). This corresponds to roughly a 0.5–1 point increase on the MMSE (30-point scale).
• Working memory (digit span): Significant improvement (SMD = 0.31, 95% CI: 0.08 to 0.54, p = 0.008).
• Executive function (Stroop test): Significant improvement (SMD = 0.25, 95% CI: 0.02 to 0.48, p = 0.03).
• Processing speed (trail making test): No significant effect (SMD = 0.12, 95% CI: −0.10 to 0.34, p = 0.28).

Subgroup analyses:

• Cognitive benefits were larger in adults aged 65+ compared to 50–65 (p for interaction = 0.04).
• Cognitive benefits were larger in adults with mild cognitive impairment at baseline compared to cognitively healthy adults (p for interaction = 0.01).
• No significant differences by sex, creatine dose, or training duration for muscle outcomes.

Safety:

• No significant changes in kidney function markers (creatinine, blood urea nitrogen) or liver enzymes.
• Adverse events were mild and similar between groups (mostly gastrointestinal discomfort, muscle cramps). No serious adverse events attributed to creatine.

To put these numbers in plain English:

• Lean body mass: Gaining 1.37 kg of muscle over 8–12 weeks is roughly equivalent to what you'd expect from 3–4 months of consistent resistance training alone. Adding creatine essentially accelerates muscle gain by about 30–50% over training alone.
• Upper body strength: A 5.2 kg increase in bench press 1RM is roughly the difference between being able to bench press a 5 kg plate on each side versus not. For a 70 kg older adult, that's about a 7% improvement in upper body pushing strength.
• Lower body strength: A 12.4 kg increase in leg press is roughly equivalent to being able to stand up from a chair without using your hands when previously you needed them — a meaningful functional gain.
• Chair stand test: An extra 1.6 stands in 30 seconds is the difference between struggling to get out of a low chair and doing it with ease. This is clinically meaningful — a 2-stand improvement is considered the minimal important difference for older adults.
• Timed up-and-go: A 0.7 second reduction is modest but meaningful. For context, a 1-second improvement is associated with a 10–15% reduction in fall risk.
• Gait speed: A 0.05 m/s increase is small — about the speed of a slow walk. However, every 0.1 m/s increase in gait speed is associated with a ~10% reduction in mortality risk in older adults.
• Cognitive function: A 0.5–1 point increase on the MMSE is small — roughly equivalent to the cognitive benefit of 6 months of aerobic exercise. For someone with mild cognitive impairment, this could be the difference between maintaining independence and needing assistance.

What the authors acknowledge:

• High heterogeneity for some outcomes (lean body mass I² = 72%, bench press I² = 65%), suggesting true effects vary across populations and protocols.
• Small number of studies contributing to cognitive outcomes (only 4–6 trials), limiting statistical power and generalisability.
• Most studies were 8–12 weeks; long-term effects (>1 year) are unknown.
• Few studies included adults with frailty or established sarcopenia; most studied healthy older adults.
• Dietary creatine intake from meat/fish was not controlled in most studies.
• Compliance with supplementation was not always verified via blood or urine markers.

Critical reader notes:

• Industry funding: Some included studies were funded by creatine manufacturers (e.g., AlzChem, Creapure®). While the meta-analysis authors declare no conflicts, the individual studies may have sponsorship bias.
• Publication bias: Funnel plot asymmetry was detected for some outcomes (e.g., bench press), suggesting possible publication bias favouring positive results.
• Cognitive assessments: The cognitive tests used (MMSE, MoCA) are screening tools, not comprehensive neuropsychological batteries. Ceiling effects are possible in cognitively healthy adults.
• Resistance training programmes varied widely: Some studies used supervised, progressive programmes; others used home-based, unsupervised training. This likely contributed to heterogeneity.
• Blinding quality: While most studies were double-blind, creatine has a distinctive taste and texture, and some participants may have correctly guessed their group assignment.
• Population limits: Nearly all participants were Caucasian; generalisability to other ethnic groups is unknown.
• No direct comparison of creatine alone (without training) versus training alone — the design only tests the combination.

For someone running their own n=1 experiment:

What to test:

• Creatine monohydrate (not creatine ethyl ester, buffered creatine, or other forms — monohydrate has the strongest evidence)
• Dose: 5 g/day (no loading phase needed for gradual effects; loading with 20 g/day for 5–7 days may speed results but increases risk of gastrointestinal discomfort)
• Combine with a progressive resistance training programme: 3 sessions per week, targeting all major muscle groups (chest press, leg press, rows, overhead press, squats or leg extensions, core work)
• Duration: Minimum 8 weeks to see measurable changes in muscle mass and strength; 12 weeks for functional and cognitive effects

Minimum meaningful duration:

• 8 weeks for strength and lean body mass changes
• 12 weeks for functional performance improvements
• 12–16 weeks for cognitive effects (if they occur)

What to measure (specific metrics):

Body composition:

• Body weight (weekly, same time of day, after voiding)
• Waist circumference (weekly)
• If available: DXA or BIA scan at baseline and 12 weeks (look for lean mass change >1 kg)
• Skinfold measurements (if trained) at baseline and 12 weeks

Strength:

• Bench press 1RM (or estimated from 5RM) at baseline, 4 weeks, 8 weeks, 12 weeks
• Leg press 1RM (or estimated from 5RM) at same intervals
• Handgrip strength (dynamometer) weekly — 3 trials per hand, record best

Functional performance:

• Chair stand test (number of stands in 30 seconds) — weekly
• Timed up-and-go (seconds) — weekly
• Gait speed over 4 metres (m/s) — weekly
• 6-minute walk distance (metres) — at baseline and 12 weeks

Cognitive function:

• Montreal Cognitive Assessment (MoCA) — at baseline and 12 weeks (online version available)
• Digit span test (forward and backward) — weekly (free apps available)
• Stroop test — weekly (free online versions)
• Subjective memory rating (1–10 scale) — daily

Safety:

• Kidney function (creatinine, blood urea nitrogen) — at baseline and 12 weeks if you have access to blood tests
• Gastrointestinal symptoms (bloating, cramping, diarrhoea) — daily log (0–3 scale)
• Muscle cramps — daily log

Key confounds to control for:

• Dietary creatine intake: Reduce or standardise meat/fish consumption. Creatine is found in red meat and fish (1–2 g per 250 g serving). If you eat a lot of meat, your baseline creatine stores are higher, and supplementation may have less effect. Consider a 2-week washout period (vegetarian diet) before starting.
• Protein intake: Ensure adequate protein (1.2–1.6 g/kg body weight per day). Creatine works synergistically with protein for muscle building. Track protein intake daily.
• Training consistency: Missed sessions reduce effect. Aim for ≥90% compliance. Log every session.
• Sleep: Poor sleep impairs muscle recovery and cognitive function. Track sleep duration and quality (7–9 hours/night target).
• Hydration: Creatine draws water into muscle cells. Dehydration can cause cramps. Aim for 2–3 litres of water per day.
• Caffeine: High-dose caffeine (>400 mg/day) may blunt creatine's effects on muscle phosphocreatine resynthesis.